COST-EFFECTIVENESS OF CORONARY ARTERY CALCIUM TO GUIDE PCSK9 INHIBITOR THERAPY AMONG PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

Jonathan Hong,Marcio Bittencourt,Ron Blankstein,Michael Shapiro,Michael Blaha,Miguel Caínzos Achirica,Salim Virani,Raul D. Santos,Khurram Nasir

COST-EFFECTIVENESS OF CORONARY ARTERY CALCIUM TO GUIDE PCSK9 INHIBITOR THERAPY AMONG PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

2020

Jonathan Hong
Marcio Bittencourt
Ron Blankstein
Michael Shapiro
Michael Blaha
Miguel Caínzos Achirica
Salim Virani
Raul D. Santos
Khurram Nasir

Familial hypercholesterolemia (FH) is associated with premature atherosclerotic cardiovascular disease (ASCVD). However, ASCVD risk is heterogeneous in individuals with FH and coronary artery calcium (CAC) can further risk stratify this population. Our objective was to determine the cost-

Keywords:

Diabetes mellitus
PCSK9
Familial hypercholesterolemia
coronary artery calcium
Medicine
Cardiology
Internal medicine
Atherosclerotic cardiovascular disease
cost effectiveness
Population

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations